| Document |
Document Title |
|
WO/2022/174803A1 |
The present invention relates to an S-configuration-containing amino benzamide pyridazinone compound, a preparation method therefor, and a pharmaceutical composition and application thereof. Specifically, the present invention relates to...
|
|
WO/2022/171265A1 |
The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I).
|
|
WO/2022/174256A1 |
The present disclosure provides compounds, or their tautomers or pharmaceutically acceptable salts thereof, and their pharmaceutical compositions that can selectively activate Yes-associated protein 1 (YAP). YAP activators of the present...
|
|
WO/2022/171745A1 |
The present invention provides new bicyclic tetrahydroazepine derivatives having the general formula (I), wherein X, Y, R1, R2, R3, R4, R5, R6, R6a are as defined herein, compositions including the compounds, processes of manufacturing t...
|
|
WO/2022/171185A1 |
The present invention provides a compound serving as an NLRP3 inhibitor. Specifically, the present invention provides a compound having a structure shown in the following formula (I), or an optical isomer, pharmaceutically acceptable sal...
|
|
WO/2022/172037A1 |
The present invention relates to compounds of Formulas A-D, I-IV and Z, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or ...
|
|
WO/2022/169780A1 |
The present disclosure provides PROTAC compounds represented by Formula (A): D-L-DSM (A), or an enantiomer, a diastereoisomer, and/or a pharmaceutically acceptable salt of any one of the foregoing, wherein: DSM is a degradation signaling...
|
|
WO/2022/166879A1 |
The present invention relates to a benzo seven-membered ring bifunctional compound and an application thereof, and in particular to a compound represented by formula (IV) and a pharmaceutically acceptable salt thereof. The compound can b...
|
|
WO/2022/166721A1 |
The present invention relates to a series of fused ring derivatives containing 1,4-oxazepane and a preparation method therefor, and in particular relates to a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/167445A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/166917A1 |
A TYK2 inhibitor compound containing a bicyclic ring and the use thereof in the preparation of a drug for treating or preventing TYK2-related diseases.
|
|
WO/2022/167819A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof Formula (I) wherein R2, R3, R4, X1, X2, X3 and X4 are as defined in the specification, processes for t...
|
|
WO/2022/166923A1 |
A phenyldihydropyrimidine compound as represented by formula I, a tautomer or a pharmaceutically acceptable salt thereof. The phenyldihydropyrimidine compound has a good anti-HBV activity and can be used for preparing drugs for treating ...
|
|
WO/2022/166938A1 |
The present invention relates to the field of herbicides, and in particular, to a uracil compound containing a carboxylate fragment and a preparation method therefor, a herbicidal composition, and a use. The uracil compound containing a ...
|
|
WO/2022/166570A1 |
A series of new-type dual-targeting degradation compounds, which have two independent inhibitor units and an E3 ligase ligand, or a pharmaceutically acceptable salt, hydrate, stereoisomer or prodrug thereof, a preparation method therefor...
|
|
WO/2022/169755A1 |
The present application discloses novel compounds of formula (I), pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a co...
|
|
WO/2022/167682A1 |
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).
|
|
WO/2022/167867A1 |
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, autoimmune disease, solid o...
|
|
WO/2022/169239A1 |
In the present invention, a NLRP3-inhibitory compound 7 (NIC7) and a potent derivative NIC7w which are a novel small-molecule inhibitor for inhibiting NLRP3 inflammasomes are identified. Specifically, the compound and the derivative inhi...
|
|
WO/2022/167457A1 |
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/162017A1 |
The invention relates to a crystalline form of 1-{(R)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluo
romethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-2-(3-
methyl-[1,2,4]triazol-1-yl)-ethanone, processes for the preparation ...
|
|
WO/2022/164135A1 |
The present invention relates to a benzothiazole or benzimidazole derivative, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same as an active ingredient for prevention or treatment of SIRTUIN 7 p...
|
|
WO/2022/160928A1 |
The present application belongs to the technical field of organic materials. Provided are a nitrogen-containing compound, and an electronic component and an electronic device containing same. The structural formula of the nitrogen-contai...
|
|
WO/2022/161166A1 |
A targeting chimeric compound, a pharmaceutical composition comprising same, a preparation method therefor and use thereof. The targeting chimeric compound is as represented by general formula (I), and each substituent in the general for...
|
|
WO/2022/157324A1 |
The present invention relates to a method for preparing 2-[2-(2-chlorothiazol-5-yl)-2- oxo-ethyl]sulfanyl-6-hydroxy-3-methyl-5-phenyl-pyrimidin-4-o
ne or a tautomer thereof, to 2-[2-(2-chlorothiazol-5-yl)-2-oxo-ethyl]sulfanyl-6-hydroxy-3...
|
|
WO/2022/156059A1 |
Disclosed are a compound as represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. Further disclosed are a method for preparing the above-mentioned compound and the use thereof in preventing and/o...
|
|
WO/2022/156764A1 |
The present invention relates to the field of biomedicine, and specifically relates to a proteolysis-targeting chimera (PROTAC) compound. The structure of the PROTAC compound can be represented by general formula LGP-LK-LGE, wherein LGP ...
|
|
WO/2022/157499A1 |
The invention relates to protected HDAC inhibitor compounds of formula I, in which Y, Ar1, Ar2, X, R1 and R2 are as defined herein. In aspects, the inventions relates to use of the compounds, and to methods of deprotecting the compounds.
|
|
WO/2022/157316A1 |
The present invention relates to a method for preparing 2-[2-(2-chlorothiazol-5-yl)-2- hydroxy-ethyl]sulfanyl-6-hydroxy-3-methyl-5-phenyl-pyrimidin
-4-one or a tautomer thereof or enantiomerically enriched forms thereof, to 2-[2-(2-chlor...
|
|
WO/2022/155941A1 |
The invention provides a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating a disease or disorder associated with CDK2.
|
|
WO/2022/156708A1 |
Provided are a PARP7 enzyme inhibitor, a composition containing the inhibitor and the use thereof, synthetic methods for the preparation of PARP7 enzyme inhibitor and useful intermediates thereof.
|
|
WO/2022/159445A1 |
The present disclosure is generally directed to activators of lipoprotein lipase useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), or a pharmaceutically acceptable salt, isomer, solvat...
|
|
WO/2022/152821A1 |
Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of formula (I). These compounds find use as modulators of cereblon, in particular in the treatment of abnormal cell growth in mammals, especially...
|
|
WO/2022/152852A1 |
This application relates to compounds of Formula (I), which are antagonists of MrgX2 (Mas-related Gene X2) and thus are useful as therapeutic agents, specifically therapeutic agents for use in the treatment of chronic spontaneous urticar...
|
|
WO/2022/152853A1 |
This application relates to compounds of Formula I which are antagonists of MrgX2 (Mas-related Gene X2) and thus are useful as therapeutic agents, specifically therapeutic agents for use in the treatment of chronic spontaneous urticaria,...
|
|
WO/2022/147694A1 |
Provided herein are novel compounds (e.g., Formula I, II, III, or IV), pharmaceutical compositions, and methods of using the same. The compounds herein can typically induce UCP-1 expression and/or browning of white adipose tissues. The c...
|
|
WO/2022/150574A1 |
Disclosed are compounds for inhibiting lipoamide dehydrogenase (Lpd), and methods of treating tuberculosis.
|
|
WO/2022/147993A1 |
Provided are a diphenylpyrazole compound as represented by formula (I) below or an agrochemically acceptable salt thereof, which is a novel inhibitor targeting pest GSTs, has a wide range of inhibitory activity on GSTs in various pests, ...
|
|
WO/2022/150384A1 |
The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having a structure according to Formula (I): wherein X1, R1, R2, m, and n are described herein.
|
|
WO/2022/148331A1 |
Provided herein are novel compounds (e.g., Formula I, II, III, or IV), pharmaceutical compositions, and methods of using the same. The compounds herein can typically induce UCP-1 expression and/or browning of white adipose tissues. The c...
|
|
WO/2022/145408A1 |
The present invention provides compounds that have a serotonin 5-HT2A receptor antagonist and/or inverse agonist activity, and pharmaceutically acceptable salts thereof, and also provides a serotonin 5-HT2A receptor antagonist and/or inv...
|
|
WO/2022/141977A1 |
Provided are a class of oral GSNOR inhibitors and a pharmaceutical use thereof, the structural features thereof being shown in formula I. Compared to N6022, the compound has good oral bioavailability and a longer half-life. In in vitro e...
|
|
WO/2022/144002A1 |
Disclosed are a derivative of a 2,5-diketopiperazine compound, and a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed are a compound as represented by formula (I), a stereoiso...
|
|
WO/2022/147210A1 |
Novel thiazole- and/or isoquinoline- containing compounds are presented that are useful for treating cancers as well as treating and/or preventing viral infections. Methods of treating and/or preventing broad-spectrum viral infections ar...
|
|
WO/2022/143773A1 |
Provided are a class of benzimidazole compounds and an application thereof as a 300/CBP inhibitor. Specifically, provided are a compound represented by formula (P) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/147246A1 |
Disclosed herein are compounds and methods of treating diseases and/or conditions associated with FGFR inhibition.
|
|
WO/2022/143771A1 |
Provided are an RORγt modulator, and a preparation method therefor and an application thereof. The RORγt modulator is selected from a compound represented by formula I, and a pharmaceutically acceptable salt, solvate, solvate of the ph...
|
|
WO/2022/135514A1 |
Provided are a class of multi-substituted uracil derivatives and a pharmaceutical composition containing such compounds, which compounds can be used as chymase inhibitors. Also provided are a method for preparing such compounds and the p...
|
|
WO/2022/140325A1 |
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided...
|
|
WO/2022/133529A1 |
This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and ...
|
